Revenue
2020
2021
2022
2023
Fermentalg (FALG)
Price—Loading quote
Net income
2020
2021
2022
2023
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2020
2021
2022
2023
Financial statements
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Revenue | €4.1M | €7.6M | €5.6M | €2.2M |
| Gross profit | €536,000 | €1.8M | €2.0M | €1.1M |
| Gross margin | 13.21% | 23.76% | 35.12% | 49.48% |
| Research & development | €4.4M | €4.8M | €4.7M | €5.8M |
| Operating expenses | €12.3M | €10.8M | €7.8M | €7.3M |
| Operating income | −€11.8M | −€9.0M | −€5.9M | −€6.2M |
| Operating margin | −290.98% | −118.07% | −103.70% | −280.27% |
| Net income | −€14.1M | −€9.9M | −€6.8M | −€6.9M |
| Net profit margin | −348.64% | −129.11% | −121.30% | −311.93% |
| Basic EPSper basic share | -€0.32 | -€0.24 | -€0.19 | -€0.32 |
| Diluted EPSper diluted share | -€0.32 | -€0.24 | -€0.19 | -€0.32 |
Owners
Reported shareholders and owner groups
19.49%of company shares
HuvePharma EOODSource updated Oct 7, 2026
View holders
| Holder | Ownership |
|---|---|
| 19.49%Oct 7, 2026 | |
| 8.30%Oct 7, 2026 | |
| 5.78%Oct 7, 2026 |
These Euronext company-profile figures report shares in the company's capital. Named holders and owner groups are shown as published; free float, treasury shares, and unspecified holders are excluded from the colored segments.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: Euronext / Cofisem ↗Checked Oct 21, 2026